Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection

Gabriela Baldeon Vaca; Michelle Meyer; Ana Cadete; Chiaowen Joyce Hsiao; Anne Golding; Albert Jeon; Eric Jacquinet; Emily Azcue; Chenxia Monica Guan; Xavier Sanchez-Felix; Colette A. Pietzsch; Chad Mire; Matthew A. Hyde; Margaret E. Comeaux; Julie M. Williams; Jean C. Sung; Andrea Carfi; Darin K. Edwards; Alexander Bukreyev; Kapil Bahl

doi:10.1126/sciadv.adh1655

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection

Gabriela Baldeon Vaca, Michelle Meyer, Ana Cadete, Chiaowen Joyce Hsiao, Anne Golding, Albert Jeon, Eric Jacquinet, Emily Azcue, Chenxia Monica Guan, Xavier Sanchez-Felix, Colette A. Pietzsch, Chad Mire, Matthew A. Hyde, Margaret E. Comeaux, Julie M. Williams, Jean C. Sung, Andrea Carfi, Darin K. Edwards, Alexander Bukreyev, Kapil Bahl

Microbiology And Immunology

Research output: Contribution to journal › Article › peer-review

Abstract

Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.

Original language	English (US)
Article number	eadh1655
Journal	Science Advances
Volume	9
Issue number	38
DOIs	https://doi.org/10.1126/sciadv.adh1655
State	Published - 2023

ASJC Scopus subject areas

General

Access to Document

10.1126/sciadv.adh1655

Cite this

Vaca, G. B., Meyer, M., Cadete, A., Hsiao, C. J., Golding, A., Jeon, A., Jacquinet, E., Azcue, E., Guan, C. M., Sanchez-Felix, X., Pietzsch, C. A., Mire, C., Hyde, M. A., Comeaux, M. E., Williams, J. M., Sung, J. C., Carfi, A., Edwards, D. K., Bukreyev, A., & Bahl, K. (2023). Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Science Advances, 9(38), Article eadh1655. https://doi.org/10.1126/sciadv.adh1655

Vaca, GB, Meyer, M, Cadete, A, Hsiao, CJ, Golding, A, Jeon, A, Jacquinet, E, Azcue, E, Guan, CM, Sanchez-Felix, X, Pietzsch, CA, Mire, C, Hyde, MA, Comeaux, ME, Williams, JM, Sung, JC, Carfi, A, Edwards, DK, Bukreyev, A & Bahl, K 2023, 'Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection', Science Advances, vol. 9, no. 38, eadh1655. https://doi.org/10.1126/sciadv.adh1655

@article{c9aa00ea44784dd6a440ed798d5e424d,

title = "Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection",

abstract = "Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.",

author = "Vaca, {Gabriela Baldeon} and Michelle Meyer and Ana Cadete and Hsiao, {Chiaowen Joyce} and Anne Golding and Albert Jeon and Eric Jacquinet and Emily Azcue and Guan, {Chenxia Monica} and Xavier Sanchez-Felix and Pietzsch, {Colette A.} and Chad Mire and Hyde, {Matthew A.} and Comeaux, {Margaret E.} and Williams, {Julie M.} and Sung, {Jean C.} and Andrea Carfi and Edwards, {Darin K.} and Alexander Bukreyev and Kapil Bahl",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors.",

year = "2023",

doi = "10.1126/sciadv.adh1655",

language = "English (US)",

volume = "9",

journal = "Science Advances",

issn = "2375-2548",

publisher = "American Association for the Advancement of Science",

number = "38",

}

TY - JOUR

T1 - Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection

AU - Vaca, Gabriela Baldeon

AU - Meyer, Michelle

AU - Cadete, Ana

AU - Hsiao, Chiaowen Joyce

AU - Golding, Anne

AU - Jeon, Albert

AU - Jacquinet, Eric

AU - Azcue, Emily

AU - Guan, Chenxia Monica

AU - Sanchez-Felix, Xavier

AU - Pietzsch, Colette A.

AU - Mire, Chad

AU - Hyde, Matthew A.

AU - Comeaux, Margaret E.

AU - Williams, Julie M.

AU - Sung, Jean C.

AU - Carfi, Andrea

AU - Edwards, Darin K.

AU - Bukreyev, Alexander

AU - Bahl, Kapil

PY - 2023

Y1 - 2023

N2 - Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.

AB - Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85172148160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85172148160&partnerID=8YFLogxK

U2 - 10.1126/sciadv.adh1655

DO - 10.1126/sciadv.adh1655

M3 - Article

C2 - 37738334

AN - SCOPUS:85172148160

SN - 2375-2548

VL - 9

JO - Science Advances

JF - Science Advances

IS - 38

M1 - eadh1655

ER -

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this